Skip to main content
. 2022 Feb 14;28(5):1072–1082. doi: 10.1038/s41591-022-01721-6

Fig. 3. Comparison of effects of factors in participants who received two doses of ChAdOx1 or BNT162b2 or had natural SARS-CoV-2 infection.

Fig. 3

a, Effects on anti-spike IgG peak levels. b, Effects on anti-spike IgG half-lives. In total, 100,639 participants received two doses of ChAdOx1; 55,053 participants received two doses of BNT162b2; and 3,271 had natural infection. Mean estimates with 95% CrIs are presented. In b, 95% CrIs are truncated at −100 and 75 days for visualization.

Source data